Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Lactococcus lactis D4 Has Potential Effect to Alleviate Inflammation and Reverse Dysbiosis in Colitis Rat Model

The Indonesian Biomedical Journal · Vol. 16 No. 2 (2024) · hlm. 199–207

DOI
10.18585/inabj.v16i2.2970
ISSN
2085-3297, 2355-9179
Terbit
2024-04-30
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Inflammatory bowel disease (IBD) is a prevalent chronic inflammatory disorder of the gastrointestinal tract that may lead to colorectal cancer if untreated. Several medications for IBD have adverse side effects. Thus, there are high interest for searching alternative treatment to treat IBD. Lactococcus lactis D4 isolated from dadih, a traditional fermented buffalo milk product, was investigated for the effect on gut inflammation and microbial composition in the colitis rat model.METHODS: Eighteen male Sprague-Dawley rats were divided into three groups; control rats, colitis-induced rats, and colitis-induced rats treated with L. lactis D4 isolate. The control group received water, while the colitis-induced rats were given azoxymethane (AOM) and dextran sodium sulphate (DSS). Rats’ feces were collected for the analysis of gut microbiota diversity by next-generation sequencing and for the measurement of transforming growth factor (TGF)-β, nuclear factor kappa-B (NF-κB), interleukin (IL)-6, and tumor necrosis factor (TNF)-α colonic expression using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).RESULTS: L. lactis D4 administration was able to reduce inflammation in colitis by decreasing IL-6 expression (0.87 vs. 0.73), while expression of TGF-β, NF-κB, and TNF-α were increased compared to the model group, suggesting a complex immunomodulatory effect. Gut microbiota sequencing revealed a similarity between the control and treatment groups, suggesting L. lactis D4 has great potential to ameliorate gut microbiota dysbiosis in colitis rats.CONCLUSION: L. lactis D4 has a beneficial effect in decreasing pro-inflammatory cytokines and is able to reserve dysbiosis in colitis rat model. Thus, L. lactis D4 might be used as a therapeutic agent for IBD.KEYWORDS: colitis, gut microbiota, inflammation, inflammatory bowel disease, Lactococcus lactis D4, probiotic, proinflammatory cytokines

Kata kunci

Jaringan kolaborasi para penulis

28 penulis · 80 tautan kepenulisan bersama · 6 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Andalas University
  • Universitas Airlangga
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Muhammad Iqbal RivaiAndalas University3
Avit SuchitraAndalas University3
Yusrawati YusrawatiAndalas University2
Ade SukmaAndalas University2
Harnavi HarunAndalas University2
Eka Fithra ElfiAndalas University1
Yose Ramda IlhamiAndalas University1
Muhamad IrsyadAndalas University1
Irawati ChaniagoAndalas University1
Liza Aulia YusfiAndalas University1
Djong Hon TjongAndalas University1
Muhammad IqbalAndalas University1
Irwan IrwanAndalas University1
Arni AmirAndalas University1
Afriwardi AfriwardiAndalas University1
Nelvianti NelsonAndalas University1
Joserizal SerudjiAndalas University1
Erry GumilarUniversitas Airlangga1
Hudila Rifa KarmiaAndalas University1
Hardisman HardismanAndalas University1
Tofrizal TofrizalAndalas University1
Deddy Satriya PutraAndalas University1
Fadil OenzilAndalas University1
Hafni BachtiarAndalas University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Lactococcus lactis D4 Has Potential Effect to Alleviate Inflammation and Reverse Dysbiosis in Colitis Rat Model</dc:title><dc:creator>Rini Suswita</dc:creator><dc:creator>Alvarino Alvarino</dc:creator><dc:creator>Eryati Darwin</dc:creator><dc:creator>Jamsari Jamsari</dc:creator><dc:subject>colitis</dc:subject><dc:subject>inflammatory bowel disease</dc:subject><dc:subject>gut dysbiosis</dc:subject><dc:subject>probiotics</dc:subject><dc:subject>fermented buffalo milk</dc:subject><dc:subject>dadih</dc:subject><dc:subject>inflammatory cytokines</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>TNF-α</dc:subject><dc:subject>TGF-beta</dc:subject><dc:subject>NF-κB</dc:subject><dc:subject>immunomodulation</dc:subject><dc:subject>colonic inflammation</dc:subject><dc:description xml:lang="en">BACKGROUND: Inflammatory bowel disease (IBD) is a prevalent chronic inflammatory disorder of the gastrointestinal tract that may lead to colorectal cancer if untreated. Several medications for IBD have adverse side effects. Thus, there are high interest for searching alternative treatment to treat IBD. Lactococcus lactis D4 isolated from dadih, a traditional fermented buffalo milk product, was investigated for the effect on gut inflammation and microbial composition in the colitis rat model.METHODS: Eighteen male Sprague-Dawley rats were divided into three groups; control rats, colitis-induced rats, and colitis-induced rats treated with L. lactis D4 isolate. The control group received water, while the colitis-induced rats were given azoxymethane (AOM) and dextran sodium sulphate (DSS). Rats’ feces were collected for the analysis of gut microbiota diversity by next-generation sequencing and for the measurement of transforming growth factor (TGF)-β, nuclear factor kappa-B (NF-κB), interleukin (IL)-6, and tumor necrosis factor (TNF)-α colonic expression using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).RESULTS: L. lactis D4 administration was able to reduce inflammation in colitis by decreasing IL-6 expression (0.87 vs. 0.73), while expression of TGF-β, NF-κB, and TNF-α were increased compared to the model group, suggesting a complex immunomodulatory effect. Gut microbiota sequencing revealed a similarity between the control and treatment groups, suggesting L. lactis D4 has great potential to ameliorate gut microbiota dysbiosis in colitis rats.CONCLUSION: L. lactis D4 has a beneficial effect in decreasing pro-inflammatory cytokines and is able to reserve dysbiosis in colitis rat model. Thus, L. lactis D4 might be used as a therapeutic agent for IBD.KEYWORDS: colitis, gut microbiota, inflammation, inflammatory bowel disease, Lactococcus lactis D4, probiotic, proinflammatory cytokines</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2024-04-30</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>http://dx.doi.org/10.18585/inabj.v16i2.2970</dc:identifier><dc:identifier>10.18585/inabj.v16i2.2970</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 16 No 2 (2024); 199-207</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/2970/707</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>